Inflammation affects the viability and plasticity of equine mesenchymal stem cells: possible implications in intra-articular treatments.
- Author:
Laura BARRACHINA
1
;
Ana Rosa REMACHA
;
Antonio ROMERO
;
Francisco José VÁZQUEZ
;
Jorge ALBAREDA
;
Marta PRADES
;
Beatriz RANERA
;
Pilar ZARAGOZA
;
Inmaculada MARTÍN-BURRIEL
;
Clementina RODELLAR
Author Information
- Publication Type:Original Article
- Keywords: horses; mesenchymal stromal cells; joint diseases; proinflammatory cytokines; synovial fluid
- MeSH: Animals; Bone Marrow; Cytokines; Horses; Inflammation*; Joint Diseases; Joints; Mesenchymal Stromal Cells*; Phenotype; Plastics*; Regeneration; Synovial Fluid
- From:Journal of Veterinary Science 2017;18(1):39-49
- CountryRepublic of Korea
- Language:English
- Abstract: Mesenchymal stem cells (MSCs) are gaining relevance for treating equine joint injuries because of their ability to limit inflammation and stimulate regeneration. Because inflammation activates MSC immunoregulatory function, proinflammatory priming could improve MSC efficacy. However, inflammatory molecules present in synovial fluid or added to the culture medium might have deleterious effects on MSCs. Therefore, this study was conducted to investigate the effects of inflammatory synovial fluid and proinflammatory cytokines priming on viability and plasticity of equine MSCs. Equine bone marrow derived MSCs (eBM-MSCs) from three animals were cultured for 72 h in media supplemented with: 20% inflammatory synovial fluid (SF); 50 ng/mL IFN-γ and TNF-α (CK50); and 20 ng/mL IFN-γ and TNF-α (CK20). Proliferation assay and expression of proliferation and apoptosis-related genes showed that SF exposed-eBM-MSCs maintained their viability, whereas the viability of CK primed-eBM-MSCs was significantly impaired. Tri-lineage differentiation assay revealed that exposure to inflammatory synovial fluid did not alter eBM-MSCs differentiation potential; however, eBM-MSCs primed with cytokines did not display osteogenic, adipogenic or chondrogenic phenotype. The inflammatory synovial environment is well tolerated by eBM-MSCs, whereas cytokine priming negatively affects the viability and differentiation abilities of eBM-MSCs, which might limit their in vivo efficacy.
